When should empagliflozin (Jardiance) be started in an adult with type 2 diabetes?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

When to Start Jardiance (Empagliflozin) in Diabetic Patients

Start empagliflozin 10 mg once daily immediately upon diagnosis of type 2 diabetes if the patient has established cardiovascular disease, heart failure, or chronic kidney disease with eGFR ≥20 mL/min/1.73 m², regardless of HbA1c level or current metformin use. 1, 2

Primary Indications for Starting Empagliflozin

1. Established Cardiovascular Disease (Highest Priority)

Start empagliflozin in any adult with type 2 diabetes who has:

  • Prior myocardial infarction
  • Acute coronary syndrome
  • Coronary revascularization
  • Stroke
  • Peripheral artery disease
  • Stable or unstable angina

This indication takes precedence over glycemic control considerations because empagliflozin reduces cardiovascular death by 38% (HR 0.62) and all-cause mortality by 32% (HR 0.68) in this population 1. The cardiovascular benefit occurs independently of glucose-lowering effects and is present even when HbA1c is well-controlled 2.

2. Heart Failure (Any Ejection Fraction)

Initiate empagliflozin 10 mg daily in patients with:

  • Heart failure with reduced ejection fraction (any NYHA class)
  • Heart failure with preserved ejection fraction (LVEF >40%)
  • With or without diabetes 3, 4

The FDA has approved empagliflozin specifically to reduce cardiovascular death and heart failure hospitalization in adults with heart failure, making this a primary indication rather than a secondary consideration 5.

3. Chronic Kidney Disease

Start empagliflozin when eGFR ≥20 mL/min/1.73 m² in patients with:

  • Albuminuria (UACR ≥200 mg/g): Strong recommendation 6, 7
  • eGFR 20-45 mL/min/1.73 m² with UACR <200 mg/g: Reasonable to initiate 7
  • Diabetic kidney disease with any degree of albuminuria 8

The 2022 ADA-KDIGO consensus specifically recommends SGLT2 inhibitors for patients with eGFR ≥20 mL/min/1.73 m² to reduce CKD progression and cardiovascular events 6.

4. High Cardiovascular Risk Without Established Disease

Consider empagliflozin in patients ≥50 years with multiple risk factors:

  • Hypertension
  • Dyslipidemia
  • Smoking
  • Obesity
  • End-organ damage (left ventricular hypertrophy, retinopathy) 2

Glycemic Control Indication

For patients without cardiovascular disease, heart failure, or CKD:

  • Start empagliflozin as second-line therapy after metformin if HbA1c remains ≥7% 1
  • Can be used as monotherapy if metformin is contraindicated or not tolerated 5
  • Initial dose: 10 mg once daily; may increase to 25 mg if additional glycemic control needed 5

Important caveat: For glycemic control alone, empagliflozin is not recommended when eGFR <30 mL/min/1.73 m² as it becomes ineffective for glucose lowering 5. However, it can still be initiated for cardiovascular/renal protection down to eGFR 20 mL/min/1.73 m² 6.

Dosing by eGFR

eGFR (mL/min/1.73 m²) Recommendation
≥45 Start 10 mg; may increase to 25 mg for glycemic control [2,5]
30-44 Start 10 mg; do not increase dose [2]
20-29 Start 10 mg for CV/renal protection only (not for glycemic control) [6,7]
<20 Insufficient data; contraindicated if on dialysis [5]

Critical Pre-Initiation Assessments

Before starting empagliflozin, check:

  1. eGFR - Must be ≥20 mL/min/1.73 m² (≥30 for glycemic indication)
  2. Volume status - Correct volume depletion first, especially in elderly or those on diuretics 2, 6
  3. Pregnancy status - Contraindicated in pregnancy/breastfeeding 2
  4. History of amputation - Use caution with prior amputation, severe peripheral vascular disease, or active diabetic foot ulcers 1

Medication Adjustments at Initiation

  • Insulin or sulfonylureas: Reduce dose by ~20% to prevent hypoglycemia 2, 6
  • Diuretics: Consider reducing dose in patients at risk for volume depletion 6
  • Continue metformin - Most trial participants were on metformin at baseline 1

Common Pitfalls to Avoid

  1. Waiting for HbA1c to rise: Don't delay initiation in patients with established ASCVD or heart failure just because HbA1c is controlled. The mortality benefit is independent of glucose lowering 1, 2.

  2. Stopping at low eGFR: Continue empagliflozin even if eGFR falls below initiation threshold during treatment, unless dialysis is started 6, 7.

  3. Discontinuing during hospitalization: Can be safely continued during heart failure hospitalization once hemodynamically stable 4.

  4. Forgetting sick day rules: Instruct patients to hold empagliflozin during acute illness, prolonged fasting, or surgery to reduce ketoacidosis risk 2, 6, 5.

Safety Monitoring

  • Genital mycotic infections: Counsel on hygiene; occurs in 10-15% of women, less in men 2, 3
  • Euglycemic DKA: Rare but serious; maintain at least low-dose insulin in insulin-requiring patients 6, 5
  • eGFR dip: Expect reversible 3-5 mL/min decline in first 4 weeks; this is not an indication to stop 6, 7
  • Volume depletion: Monitor blood pressure, especially in elderly or those on diuretics 2, 6

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.